News & Media
This is our Xequel. Get ready to watch an exciting story unfold. Read all about it below, and reach out to learn more.
Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
– Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury – – Xequel Launches New
Xequel Bio Expands Leadership Team With Appointments Of Dr. Michael J. Brubaker As Chief Scientific Officer And Tony C. Tipton As Chief Operating Officer
Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Charleston, SC and Fort Worth, TX, July 26, 2022 –
Xequel Bio Announces Positive Results From Phase 1b Study Of INexinTM, A Novel ACT1 Ophthalmic Solution
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance
Xequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth
Jerry St. Peter Named Chief Executive Officer and Member of the Board of Directors Wes Brazell Named Chief Financial Officer
